Citation Impact
Citing Papers
The clinical symptoms of Parkinson's disease
2016 Standout
Gastric emptying in Parkinson's disease
1996
Parkinson disease
2017 Standout
Parkinson's disease
2021 Standout
Gastrointestinal dysfunction in Parkinson's disease
2003 Standout
Neural mechanism underlying acupuncture analgesia
2008 Standout
Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients
2001
Descending control of pain
2002 Standout
Levodopa motor complications in Parkinson's disease
2000
Therapeutic applications of compounds in the Magnolia family
2011 Standout
Dystonia in parkinson's disease: Clinical and pharmacological features
1988
Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes
2006 Standout
Levodopa in the treatment of Parkinson’s disease
2009
The spectrum of “off” in Parkinson's disease: What have we learned over 40 years?
2018
Parkinson's disease
2009 Standout
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
2001
Diagnostic Criteria for Parkinson Disease
1999 Standout
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa
2000 Standout
Parkinson's disease
2015 Standout
Oxidative stress in Parkinson's disease
2003 Standout
Five-Year Follow-up of Bilateral Stimulation of the Subthalamic Nucleus in Advanced Parkinson's Disease
2003 Standout
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study
2019
Current management of motor fluctuations in patients with advanced Parkinson’s disease treated chronically with levodopa
1999
From off-period dystonia to peak-dose chorea: The clinical spectrum of varying subthalamic nucleus activity
1999
The induction of pain: an integrative review
1999
Non-motor features of Parkinson disease
2017 Standout
Gastric emptying time and gastric motility in patients with Parkinson's disease
2001
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
2010 Standout
Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls
2016 Standout
Nociceptors: the sensors of the pain pathway
2010 StandoutNobel
Parkinson's Disease
2003 Standout
Levodopa-Induced Neurotoxicity
1997
A Mitochondrial Paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary Medicine
2005 Standout
Artificial intelligence in drug discovery and development
2020 Standout
The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.
1989
eToxPred: a machine learning-based approach to estimate the toxicity of drug candidates
2019
Diagnosis and Treatment of Parkinson Disease
2020 Standout
Levodopa and the Progression of Parkinson's Disease
2004
Levodopa-induced dyskinesia in Parkinson disease
2018
Novel formulations and modes of delivery of levodopa
2014
A reliable and simple method for simultaneous determination of dopa and 3-O-methyldopa in plasma and brain
1972
Amine Precursors and Depression
1975
Biogenic Amines and Depression
1975 Standout
?On-off? phenomenon in Parkinson's disease: Correlation to the concentration of dopa in plasma
1984 StandoutNobel
The dopaminergic response in multiple system atrophy.
1992
COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPA
1982
Variability of L-Dopa Absorption in Man
1974
The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway
2001 StandoutNobel
Second consensus statement on the diagnosis of multiple system atrophy
2008 Standout
Functional and biochemical aspects of catecholamine metabolism in brain under hypoxia
1975 StandoutNobel
Works of Muenter being referenced
Dihydroxyphenylalanine (DOPA) in plasma during dopa treatment of patients with Parkinson's disease.
1970
3-O-Methyldopa in Parkinson's disease.
1974
Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.
1977
3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease.
1973
Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
1970
L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.
1971